|
|
|
|
For companies manufacturing AAV therapies, varying time pressures and regulatory pathways, coupled with the complexity of manufacturing AAV products and the challenges linked to controlling their costs, underscore the importance of improving the efficiency of these processes.
|
|
|
|
|
Finding the optimal medium is critical to achieving cell growth and AAV titer goals. Here, we describe the development of a novel cell culture medium for AAV production with multiple HEK293 lineages. With this approach, the highest VCD and AAV titers can be achieved without the bottleneck of a non-optimized step in the AAV production process.
|
|
|
|
|
Explore a platform that provides a highly performant rhabdovirus-free Baculovirus Expression Vector System (BEVS) alternative for the BEVS production of biologics. This platform combines a chemically defined medium with a proven Sf-9-rhabdovirus-negative insect cell line.
|
|
|
|
|
To address concerns with traditional viral vector production processes and help usher in a new era of next-generation therapeutics, a scalable, transfection-based solution has been developed. Learn how this platform can dramatically reduce the time to commercial production to help you bring your viral gene therapy to patients with speed and confidence.
|
|
|
|
|
|
|
